134 related articles for article (PubMed ID: 33951544)
1. Lurbinectedin for metastatic small-cell bladder carcinoma.
Boudin L; Patient M; Romeo E; Bladé JS; de Lesquen H
Eur J Cancer; 2021 Jul; 151():1-2. PubMed ID: 33951544
[No Abstract] [Full Text] [Related]
2. Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy.
Moussa MJ; Khandelwal J; Wilson NR; Naik SA; Subbiah V; Campbell MT; Msaouel P; Singh P; Alhalabi O
Curr Oncol; 2024 Jun; 31(6):3342-3349. PubMed ID: 38920737
[TBL] [Abstract][Full Text] [Related]
3. Lurbinectedin.
Am J Health Syst Pharm; 2020 Oct; 77(22):1815-1817. PubMed ID: 32930706
[No Abstract] [Full Text] [Related]
4. Lurbinectedin for BRCA-mutated advanced breast cancer.
Gourd E
Lancet Oncol; 2018 Nov; 19(11):e582. PubMed ID: 30269906
[No Abstract] [Full Text] [Related]
5. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer.
Singh S; Jaigirdar AA; Mulkey F; Cheng J; Hamed SS; Li Y; Liu J; Zhao H; Goheer A; Helms WS; Wang X; Agarwal R; Pragani R; Korsah K; Tang S; Leighton J; Rahman A; Beaver JA; Pazdur R; Theoret MR; Singh H
Clin Cancer Res; 2021 May; 27(9):2378-2382. PubMed ID: 33288660
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
Jimeno A; Sharma MR; Szyldergemajn S; Gore L; Geary D; Diamond JR; Fernandez Teruel C; Soto Matos-Pita A; Iglesias JL; Cullell-Young M; Ratain MJ
Invest New Drugs; 2017 Aug; 35(4):471-477. PubMed ID: 28105566
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
Benton CB; Chien KS; Tefferi A; Rodriguez J; Ravandi F; Daver N; Jabbour E; Jain N; Alvarado Y; Kwari M; Pierce S; Maiti A; Hornbaker M; Santos MA; Martinez S; Siguero M; Zblewski D; Al-Kali A; Hogan WJ; Kantarjian H; Pardanani A; Garcia-Manero G
Hematol Oncol; 2019 Feb; 37(1):96-102. PubMed ID: 30153704
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine.
van Andel L; Rosing H; Lubomirov R; Avilés P; Fudio S; Tibben MM; Nan-Offeringa L; Schellens JHM; Beijnen JH
J Pharm Biomed Anal; 2018 Sep; 158():160-165. PubMed ID: 29883879
[TBL] [Abstract][Full Text] [Related]
10. Small cell carcinoma of the urinary bladder with hypercalcemia.
Sendur MA; Aksoy S; Arık Z; Yaman S; Ozdemir NY; Uncu D; Zengin N
Med Oncol; 2012 Jun; 29(2):827-8. PubMed ID: 21499925
[No Abstract] [Full Text] [Related]
11. Successful treatment of metastatic small cell carcinoma of the bladder with methotrexate, vinblastine, doxorubicin and cisplatin therapy.
Cheng DL; Unger P; Forscher CA; Fine EM
J Urol; 1995 Feb; 153(2):417-9. PubMed ID: 7815604
[TBL] [Abstract][Full Text] [Related]
12. [A Case of Small Cell Carcinoma of the Bladder].
Ota H; Yamaguchi T; Tsuruta M; Fuchigami Y; Magaribuchi T; Naito H; Iguchi R; Shibasaki N; Terai A
Hinyokika Kiyo; 2020 Sep; 66(9):313-317. PubMed ID: 32988169
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients.
Aviles P; Altares R; van Andel L; Lubomirov R; Fudio S; Rosing H; Márquez Del Pino FM; Tibben MM; Benedit G; Nan-Offeringa L; Luepke Estefan XE; Francesch A; Zeaiter A; Cuevas C; Schellens JHM; Beijnen JH
Drug Metab Dispos; 2022 Apr; 50(4):327-340. PubMed ID: 35042701
[TBL] [Abstract][Full Text] [Related]
14. Small cell carcinoma of the urinary bladder: a case of remarkable remission with combined chemotherapy.
Itoh K; Kyakuno M; Sakai H; Kokado Y; Sagawa S; Shin T
Hinyokika Kiyo; 1988 Aug; 34(8):1443-7. PubMed ID: 2848402
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review.
Rajput PS; Khan SR; Singh P; Chawla PA
Anticancer Agents Med Chem; 2022; 22(5):812-820. PubMed ID: 34229593
[TBL] [Abstract][Full Text] [Related]
16. A Baffled Mind: A Mysterious Presentation of Small-Cell Carcinoma of the Bladder.
Imran TF; Wang Y; Zhang S; Hussain MU; Srinivas S
Clin Genitourin Cancer; 2015 Aug; 13(4):e329-e332. PubMed ID: 25733058
[No Abstract] [Full Text] [Related]
17. Review: treatment of small cell carcinoma of the urinary bladder: can we learn from small cell lung cancer?
Bex A
Clin Adv Hematol Oncol; 2008 May; 6(5):385-6. PubMed ID: 18516029
[No Abstract] [Full Text] [Related]
18. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.
Erba E; Romano M; Gobbi M; Zucchetti M; Ferrari M; Matteo C; Panini N; Colmegna B; Caratti G; Porcu L; Fruscio R; Perlangeli MV; Mezzanzanica D; Lorusso D; Raspagliesi F; D'Incalci M
Biochem Pharmacol; 2017 Nov; 144():52-62. PubMed ID: 28782526
[TBL] [Abstract][Full Text] [Related]
19. Primary desmoplastic small round cell tumor of urinary bladder.
Diao B; Li F; Li G; Chen Z; Bi C
J Clin Oncol; 2010 Jun; 28(18):e291-4. PubMed ID: 20458037
[No Abstract] [Full Text] [Related]
20. New Drugs, New Indications for Various Cancers.
Aschenbrenner DS
Am J Nurs; 2020 Nov; 120(11):26-27. PubMed ID: 33105220
[No Abstract] [Full Text] [Related]
[Next] [New Search]
